RIPK1-IN-35
RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC50 of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS -induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis[1].
Product Specifications
UNSPSC
12352005
Target
Necroptosis; RIP kinase
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
O=C(NC1=NNC(C2=CC=C3N(CCOC3=C2)C(CC4=C(C=CC(OC(F)F)=C4)F)=O)=C1)C5=NN(C([2H])([2H])[2H])C(C=C5)=O
Molecular Formula
C26H18D3F3N6O5
Molecular Weight
557.50
References & Citations
[1]Tao Q, et al. Discovery of a 1H-Pyrazol-3-Amine Derivative as a Novel, Selective, and Orally Available RIPK1 Inhibitor for the Treatment of Inflammatory Disease. J Med Chem. 2025 Oct 23;68 (20) :21766-21785.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RIPK1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680669-500 1x 500 µL
P27 / KIP1 (SX53G8), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC042284-100 1x 100 µL
Human IgG4 (Ig Heavy Constant Gamma 4) (G4m Marker) (rIGHG4/1345), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041957-100 1x 100 µL
Filaggrin (Keratinocyte Differentiation Marker) (FLG/1957R), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402889-100 1x 100 µL
Secretory Component / ECM1 (ECM1/2889R), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC042217-500 1x 500 µL
CD56 / NCAM1 / NKH1 (Neuronal Cell Marker) (NCAM1/2217R), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details